Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:AVDL NASDAQ:ETNB NASDAQ:MRNS NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.82-4.7%$3.33$1.24▼$4.08$747.71M1.023.54 million shs11.79 million shsAVDLAvadel Pharmaceuticals$16.20-0.2%$13.31$6.38▼$16.66$1.57B1.581.47 million shs2.34 million shsETNB89BIO$14.87-0.6%$9.51$4.16▼$15.06$2.21B1.275.50 million shs27.33 million shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.94 million shs260 shsWVEWAVE Life Sciences$6.89-1.0%$8.43$5.28▼$16.74$1.10B-1.152.25 million shs2.20 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-4.41%-11.60%-23.37%+108.89%AVDLAvadel Pharmaceuticals0.00%+5.19%+9.31%+76.47%+18.68%ETNB89BIO0.00%+84.26%+61.81%+47.52%+78.94%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-63.64%WVEWAVE Life Sciences0.00%-1.15%-29.41%+4.87%+25.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.82-4.7%$3.33$1.24▼$4.08$747.71M1.023.54 million shs11.79 million shsAVDLAvadel Pharmaceuticals$16.20-0.2%$13.31$6.38▼$16.66$1.57B1.581.47 million shs2.34 million shsETNB89BIO$14.87-0.6%$9.51$4.16▼$15.06$2.21B1.275.50 million shs27.33 million shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.94 million shs260 shsWVEWAVE Life Sciences$6.89-1.0%$8.43$5.28▼$16.74$1.10B-1.152.25 million shs2.20 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-4.41%-11.60%-23.37%+108.89%AVDLAvadel Pharmaceuticals0.00%+5.19%+9.31%+76.47%+18.68%ETNB89BIO0.00%+84.26%+61.81%+47.52%+78.94%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-63.64%WVEWAVE Life Sciences0.00%-1.15%-29.41%+4.87%+25.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.00Buy$6.75139.36% UpsideAVDLAvadel Pharmaceuticals 3.11Buy$20.8628.75% UpsideETNB89BIO 2.56Moderate Buy$25.8173.59% UpsideMRNSMarinus Pharmaceuticals 2.44Hold$3.92613.29% UpsideWVEWAVE Life Sciences 2.93Moderate Buy$20.33195.11% UpsideCurrent Analyst Ratings BreakdownLatest AKBA, WVE, AVDL, ETNB, and MRNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/19/2025ETNB89BIORaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Market Perform9/19/2025ETNB89BIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$14.509/19/2025ETNB89BIOWolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform9/13/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating9/5/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $36.009/4/2025WVEWAVE Life SciencesB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/4/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$21.00 ➝ $18.009/4/2025ETNB89BIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.009/3/2025WVEWAVE Life SciencesLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$26.009/3/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/3/2025AVDLAvadel PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$203.73M3.67N/AN/A($0.23) per share-12.26AVDLAvadel Pharmaceuticals$221.08M7.12N/AN/A$0.77 per share21.04ETNB89BION/AN/AN/AN/A$3.34 per shareN/AMRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77WVEWAVE Life Sciences$93.95M11.67N/AN/A$1.37 per share5.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A270.00N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)ETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%11/6/2025 (Estimated)MRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%N/AWVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)Latest AKBA, WVE, AVDL, ETNB, and MRNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/7/2025Q2 2025ETNB89BIO-$0.49-$0.71-$0.22-$0.71N/AN/A7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.611.981.84AVDLAvadel PharmaceuticalsN/A2.792.38ETNB89BIO0.0715.1915.19MRNSMarinus PharmaceuticalsN/A1.661.47WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%AVDLAvadel Pharmaceuticals69.19%ETNB89BION/AMRNSMarinus Pharmaceuticals98.80%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%AVDLAvadel Pharmaceuticals5.20%ETNB89BIO2.60%MRNSMarinus Pharmaceuticals5.46%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430265.15 million257.19 millionOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableETNB89BIO40148.31 million144.45 millionOptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableAKBA, WVE, AVDL, ETNB, and MRNS HeadlinesRecent News About These CompaniesWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 19 at 2:13 AM | marketbeat.com3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025September 18 at 12:36 PM | zacks.comWave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor ConferencesSeptember 18 at 8:30 AM | globenewswire.comWAVE Life Sciences (NASDAQ:WVE) Stock Price Down 3.5% - What's Next?September 13, 2025 | marketbeat.comWave Life Sciences (WVE) Sees Promising Results From RestorAATion-2 StudySeptember 10, 2025 | finance.yahoo.comRaymond James Reaffirms Their Buy Rating on Wave Life Sciences (WVE)September 9, 2025 | theglobeandmail.comPolar Asset Management Partners Inc. Has $221,000 Stock Holdings in WAVE Life Sciences Ltd. $WVESeptember 9, 2025 | marketbeat.comLeerink Partnrs Has Positive Outlook of WVE FY2027 EarningsSeptember 9, 2025 | marketbeat.comWave Life Sciences Announces Positive Results for WVE-006 StudySeptember 8, 2025 | theglobeandmail.comTrexquant Investment LP Sells 215,940 Shares of WAVE Life Sciences Ltd. $WVESeptember 7, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Stock Position Boosted by Invesco Ltd.September 7, 2025 | marketbeat.comB. Riley ‘aggressive’ buyer of Wave Life on ‘material disconnect’September 6, 2025 | finance.yahoo.comHC Wainwright Reiterates "Buy" Rating for WAVE Life Sciences (NASDAQ:WVE)September 5, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Shares Gap Down - Should You Sell?September 5, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Shares Purchased by Adage Capital Partners GP L.L.C.September 5, 2025 | marketbeat.comWave Crashes Despite Successful RNA Editing in AATD StudySeptember 4, 2025 | biospace.comB683 Capital Management LLC Purchases 140,000 Shares of WAVE Life Sciences Ltd. $WVESeptember 4, 2025 | marketbeat.comJump Financial LLC Trims Stake in WAVE Life Sciences Ltd. $WVESeptember 4, 2025 | marketbeat.comWave RNA editing restores enzyme in genetic condition but underwhelms investorsSeptember 4, 2025 | fiercebiotech.comFWave shares sink on new study results for RNA editing drugSeptember 4, 2025 | finance.yahoo.comForecasting The Future: 7 Analyst Projections For WAVE Life SciencesSeptember 4, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKBA, WVE, AVDL, ETNB, and MRNS Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$2.82 -0.14 (-4.73%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$2.84 +0.02 (+0.71%) As of 09/19/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Avadel Pharmaceuticals NASDAQ:AVDL$16.20 -0.03 (-0.18%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$16.11 -0.09 (-0.53%) As of 09/19/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.89BIO NASDAQ:ETNB$14.87 -0.09 (-0.60%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$14.89 +0.02 (+0.13%) As of 09/19/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Marinus Pharmaceuticals NASDAQ:MRNSMarinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.WAVE Life Sciences NASDAQ:WVE$6.89 -0.07 (-1.01%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$6.92 +0.03 (+0.44%) As of 09/19/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
